Alzheimer's Disease

A self-administered assessment tool was effective in identifying cognitive impairment vs. routine care in primary care settings, according to results recently published in Frontiers in Medicine.

Individuals diagnosed with glaucoma may benefit from increased monitoring for dementia symptoms, particularly if they were diagnosed at age 80 years or older, according to a study in Ophthalmology.

In a phase 2/3 clinical trial, treatment with buntanetap was linked to cognitive gains as well as tau reduction at 12 weeks in those exhibiting mild to moderate symptoms of Alzheimer’s disease, according to the drug’s manufacturer.

Prothena Corp. recently announced it would receive $80 million from Bristol Myers Squibb for an exclusive global license to an investigational therapeutic developed to address protein dysregulation.

BOSTON — Menopause is a neurologic transition involving metabolic and immune systems of the brain, and timely estrogen therapy could reduce the risk for developing dementias and other neurogenerative diseases, according to a speaker.

The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.

Otsuka Pharmaceutical has terminated its development of AVP-786, a novel compound that was being researched as a potential treatment for patients with agitation due to Alzheimer’s disease, according to a company-issued press release.

Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a treatment for early Alzheimer’s disease in long-term study extensions, according to a company-issued press release.

Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.